Trexquant Investment LP Makes New $18.79 Million Investment in IQVIA Holdings Inc. $IQV

Key Points

• Trexquant Investment LP purchased 106,556 shares of IQVIA Holdings Inc., valued at approximately $18.8 million, during the first quarter of 2023, bringing its ownership to 0.06% of the company.
• In the same time frame, Pacer Advisors Inc. increased its holdings by 5,036.1%, now owning 871,704 shares worth around $153.7 million, while overall institutional ownership of IQVIA stands at 89.62%.
• IQVIA recently reported $2.81 EPS for the last quarter, exceeding analysts' expectations, with a net margin of 7.88% and raising its fiscal year 2025 guidance to 11.750-12.050 EPS.

Trexquant Investment LP acquired a new stake in IQVIA Holdings Inc. (NYSE:IQV - Free Report) in the first quarter, according to the company in its most recent filing with the SEC. The firm acquired 106,556 shares of the medical research company's stock, valued at approximately $18,786,000. Trexquant Investment LP owned about 0.06% of IQVIA at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in IQV. American National Bank & Trust bought a new position in IQVIA in the 1st quarter valued at approximately $26,000. Clal Insurance Enterprises Holdings Ltd raised its holdings in IQVIA by 436.7% in the 1st quarter. Clal Insurance Enterprises Holdings Ltd now owns 161 shares of the medical research company's stock valued at $28,000 after buying an additional 131 shares during the last quarter. Golden State Wealth Management LLC raised its holdings in IQVIA by 295.5% in the 1st quarter. Golden State Wealth Management LLC now owns 174 shares of the medical research company's stock valued at $31,000 after buying an additional 130 shares during the last quarter. AllSquare Wealth Management LLC bought a new position in IQVIA in the 1st quarter valued at approximately $33,000. Finally, ST Germain D J Co. Inc. raised its holdings in IQVIA by 66.1% during the 1st quarter. ST Germain D J Co. Inc. now owns 191 shares of the medical research company's stock worth $34,000 after purchasing an additional 76 shares during the last quarter. Institutional investors own 89.62% of the company's stock.

IQVIA Stock Down 3.6%

NYSE IQV traded down $6.87 during mid-day trading on Tuesday, hitting $183.94. The company's stock had a trading volume of 533,095 shares, compared to its average volume of 1,932,288. The company's 50 day simple moving average is $177.74 and its 200 day simple moving average is $167.49. IQVIA Holdings Inc. has a twelve month low of $134.65 and a twelve month high of $252.69. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.45. The firm has a market capitalization of $31.27 billion, a price-to-earnings ratio of 26.62, a PEG ratio of 2.09 and a beta of 1.32.

IQVIA (NYSE:IQV - Get Free Report) last posted its quarterly earnings results on Tuesday, July 22nd. The medical research company reported $2.81 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.77 by $0.04. IQVIA had a net margin of 7.88% and a return on equity of 30.05%. The business had revenue of $4.02 billion during the quarter, compared to the consensus estimate of $3.96 billion. During the same quarter last year, the firm posted $2.64 EPS. IQVIA's revenue was up 5.3% compared to the same quarter last year. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. Analysts anticipate that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on IQV shares. JPMorgan Chase & Co. reduced their price objective on shares of IQVIA from $232.00 to $177.00 and set an "overweight" rating on the stock in a research note on Monday, May 19th. Robert W. Baird upped their price objective on shares of IQVIA from $159.00 to $196.00 and gave the company a "neutral" rating in a research note on Wednesday, July 23rd. Evercore ISI upped their price objective on shares of IQVIA from $170.00 to $180.00 and gave the company an "outperform" rating in a research note on Wednesday, July 9th. Redburn Partners set a $188.00 price objective on shares of IQVIA in a research note on Friday, May 23rd. Finally, Citigroup reaffirmed a "neutral" rating on shares of IQVIA in a research note on Thursday, May 22nd. Seventeen research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $228.62.

Insider Buying and Selling at IQVIA

In related news, insider Keriann Cherofsky sold 549 shares of IQVIA stock in a transaction on Wednesday, July 23rd. The shares were sold at an average price of $191.53, for a total value of $105,149.97. Following the completion of the sale, the insider owned 2,910 shares of the company's stock, valued at approximately $557,352.30. This trade represents a 15.87% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Eric Sherbet sold 5,800 shares of IQVIA stock in a transaction on Wednesday, July 23rd. The stock was sold at an average price of $190.05, for a total transaction of $1,102,290.00. Following the transaction, the insider directly owned 27,178 shares in the company, valued at $5,165,178.90. This represents a 17.59% decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 1.60% of the company's stock.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.